Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Get to know the CDC recommendation for MenACWY vaccination
CDC recommends 2 doses of MenACWY—a primary dose at age 11-12 and a booster at 16—for all adolescents1
The CDC emphasizes the importance of vaccines for 16-year-olds.
In 2017, the CDC updated their immunization schedule for adolescents ≤18 years of age, adding a 16-year-old age column to their table of recommendations.2,3
The change was designed to address a problem.
According to Immunize.org the new “16-year-old” column brings much-needed attention to the fact that several CDC-recommended vaccinations due to be administered at 16 years of age are being overlooked by many providers.2
There are 2 different types of vaccines to help protect against the 5 vaccine-preventable meningococcal serogroups: 1 for serogroups ACWY and 1 for serogroup B.4,5
According to 2021 CDC survey data, only 60% of 17-year olds received a primary AND booster dose of a MenACWY vaccine6
CDC=Centers for Disease Control and Prevention; MenACWY=meningococcal serogroups A, C, W, Y.
References
- Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62(2):1-30.
- Wexler D. Immunize.org. Technically speaking: New “16-year-old vaccination platform” highlighted in 2017 US child/teen immunization schedule. http://www.immunize.org/technically-speaking/20170222.asp. Updated May 26, 2017. Accessed February 5, 2020.
- Centers for Disease Control and Prevention. Immunization schedules: Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2020. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html. Reviewed February 3, 2020. Accessed February 5, 2020.
- Centers for Disease Control and Prevention. Meningococcal vaccination for adolescents: Information for healthcare professionals. http://www.cdc.gov/vaccines/vpd/mening/hcp/adolescent-vaccine.html. Updated July 26, 2019. Accessed February 3, 2020.
- Centers for Disease Control and Prevention. Vaccines and preventable diseases: Meningococcal vaccination. https://www.cdc.gov/vaccines/vpd/mening/index.html. Updated July 26, 2019. Accessed February 11, 2020.
- Pingali C, Yankey D, Elam-Evans LD, et al. National vaccination coverage among adolescents aged 13–17 years—National Immunization Survey-Teen, United States, 2021. MMWR. 2022;71(35):1101-1108.
INDICATION
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.
IMPORTANT SAFETY INFORMATION FOR MENVEO
- Do not administer MENVEO to individuals with a severe allergic reaction (eg, anaphylaxis) to a previous dose of MENVEO, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
- Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of MENVEO
- Syncope (fainting) has occurred in association with administration of MENVEO. Procedures should be in place to avoid injury from fainting
- Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to MENVEO
- Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroups A, C, Y, and W, even if they develop antibodies following vaccination with MENVEO
- Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer MENVEO to individuals with a history of GBS should take into account the expected benefits and potential risks
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. A decision about when to administer MENVEO to an infant born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination
- Common solicited adverse reactions among children initiating vaccination: at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea; at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea; at 2 through 10 years of age who received MENVEO were injection site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site, headache, myalgia, malaise, and nausea. Across all age groups, some events were severe. Similar rates of solicited adverse reactions among adolescents and adults were observed following a single booster dose
- In two clinical studies, there were no notable differences in frequency and severity of solicited adverse reactions in individuals who received MENVEO 1-vial presentation compared to individuals who received the 2-vial presentation
- Vaccination with MENVEO may not result in protection in all vaccine recipients
Trademarks are property of their respective owners.
